Eli Lilly and Company shared additional Phase 3 outcomes for its investigational weight-loss drug retatrutide, releasing data presented at the American Diabetes Association Scientific Sessions and published in The Lancet. The molecule, a single triple hormone receptor agonist, produced large average reductions in body weight in the pivotal TRIUMPH-1 study and delivered clinically meaningful benefits across a range of obesity-related measures.
In the 80-week TRIUMPH-1 trial that enrolled adults with obesity, participants randomized to a 12 mg dose of retatrutide lost an average of 70.3 pounds - equal to a 28.3% reduction in body weight. The data also show that 65.3% of people receiving the highest tested dose achieved a body mass index below 30, which places them outside the clinical definition for obesity.
Beyond the trial's primary weight outcomes, investigators included nested basket studies to evaluate commonly co-occurring conditions. Among participants with knee problems related to excess weight, retatrutide reduced pain from osteoarthritis by as much as 73.1%. In participants with moderate-to-severe obstructive sleep apnea, the compound lowered severity scores by 60.6%.
Results from TRANSCEND-T2D-1, a 40-week trial in adults with type 2 diabetes, were published at the same time. That study reported average blood sugar improvements of up to 2.0% and found that nearly half of treated participants reached normal glycemic levels while also losing an average of 16.8% of their body weight.
"In TRIUMPH-1 and TRANSCEND-T2D-1, treatment with retatrutide resulted in substantial weight reduction together with clinically meaningful improvements in glycemia, knee osteoarthritis pain, and obstructive sleep apnea, with many individuals reaching what are classified as healthy-range weight and normal blood sugar levels," said Dr. Ania Jastreboff, lead investigator and Director of the Yale Obesity Research Center. "These findings demonstrate what may be possible when we treat obesity and impact overall health, and what this could mean for people living with obesity and its related complications."
Cardiometabolic measures also improved in the trials. Triglyceride levels fell by up to 41.0% and systolic blood pressure decreased by as much as 12.3 mmHg in trial participants, according to the published material.
The reports note treatment-emergent adverse events consistent with the class, principally gastrointestinal symptoms such as nausea and diarrhea. These side effects contributed to an 11.3% discontinuation rate at the highest dose evaluated in TRIUMPH-1.
"Across TRIUMPH-1 and TRANSCEND-T2D-1, retatrutide delivered substantial weight loss, meaningful A1C reduction, and improvements in knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea, a breadth and magnitude of outcomes that's striking to see with a single therapy," said Kenneth Custer, executive vice president at Lilly Cardiometabolic Health. "By addressing weight, glycemia and obesity-related complications together, these results highlight retatrutide's potential across the cardiometabolic spectrum and reinforce our commitment to delivering options that meet patients' needs and preferences."
Lilly's announcement arrives during an active development race for next-generation weight-management medicines in a market the company says is projected to exceed $100 billion by the 2030s. At the same conference, Pfizer Inc. presented Phase 2b findings for its investigational candidate berobenatide, which produced a 15.9% weight reduction at 32 weeks.
The combined body of evidence positions retatrutide as a potential successor to existing dual-agonist therapies, given the magnitude of weight loss, glycemic control and improvements in obesity-related complications observed in these trials. The published materials and conference presentation underscore both the therapeutic breadth and the tolerability profile, which includes a measurable rate of discontinuation tied to gastrointestinal adverse events.
What this means for affected sectors
- Pharmaceuticals and biotech companies focused on obesity and metabolic disease could see altered competitive dynamics depending on regulatory outcomes and commercial uptake.
- Healthcare payers, providers and the durable medical equipment sector that treats obesity-related complications may be affected by shifts in clinical outcomes if such therapies become widely adopted.
- Consumer health markets tied to weight management may experience downstream impacts if single-molecule therapies substantially change treatment paradigms for obesity and its comorbidities.